AlzeCure Receives Additional Subscription Commitments of Approximately SEK 7 million in the Ongoing Rights Issue
STOCKHOLM, SE / / July 16, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB ("AlzeCure" or the "Company") has received additional subscription commitments of SEK 7 million from a group of qualified investors in the Company's ongoing rights issue announced on June 16, 2025 (the "Rights Issue"). Should the issue be oversubscribed, the Company intends to utilize the remaining portion of the Over-Allotment Option, following the previously announced additional subscription commitment, to accommodate these subscriptions to the greatest extent possible.
In addition to previously entered subscription commitments, a group of qualified investors have committed to subscribe for shares amounting to approximately SEK 7 million, corresponding to about 14 percent of the Rights Issue. The subscription commitments are based on the same terms as for other investors, i.e. no remuneration. In the event the issue is oversubscribed and the allocation under these additional subscription commitments cannot be fully allocated, the Company intends to utilize the remaining portion of the Over-Allotment Option of around SEK 5 million to accommodate theses subscription to the greatest extent possible in accordance with the principle that allocation under the overallotment option shall primarily be made to strategic and/or qualified investors.
Following these additional subscription commitments, the total amount of subscription commitments entered into amounts to approximately SEK 32 million, corresponding to around 66 percent of the total amount of the Rights Issue of approximately SEK 48.5 million, with an over-allotment option of SEK 10 million.
"At AlzeCure Pharma, we are very pleased with the interest and support we are seeing for the share issue, both from existing major shareholders and new investors. This demonstrates confidence in the share issue and the plans it is intended to finance, which primarily include preparations for the upcoming Phase 2 study in Alzheimer's patients with NeuroRestore ACD856 - a project for which we have secured funding from the European Innovation Council. We are very proud of this support, which can also be seen as a validation of the project," says Martin Jönsson, CEO of AlzeCure.
Additional subscription commitments:
Investor
Subscription commitment, SEK
Jan Poulsen
2,000,000
Niklas Estensson
1,000,000
Christian Månsson
1,000,000
Rose-Marie Karlsson
1,000,000
Alexander Schoeneck
1,000,000
AV Linbo Invest AB
660,000
Johan Wiklund
308,000
TOTAL
6,968,000
The subscription period for the share issue runs through July 22. More information is available at: www.alzecurepharma.com
Advisors
AlzeCure has engaged Zonda Partners AB and Synch Advokat AB as financial and legal advisors, respectively, in connection with the Rights Issue. In connection with the additional subscription commitment addressed in this press release, Corpura Fondkommission AB has also acted as joint bookrunner.
Important information
The information in this press release does not contain or constitute an offer to acquire, subscribe for, or otherwise trade in shares, subscription warrants, or other securities in AlzeCure. No action has been taken, and no actions will be taken, to permit a public offering in any jurisdiction other than Sweden. Any invitation to eligible persons to subscribe for shares in AlzeCure will only be made through the supplementary Information Document published by AlzeCure on 7 July 2025.
The information in this press release may not be announced, published, or distributed, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, Singapore, South Africa, the United States, Belarus, Russia, South Korea, Switzerland, or any other jurisdiction where such action would be unlawful, subject to legal restrictions, or would require actions other than those required under Swedish law. Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
For more information, please contact
Martin Jönsson, CEOTel: +46 707 86 94 43martin.jonsson@alzecurepharma.com
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.
FNCA Sweden AB is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se.
Attachments
AlzeCure Receives Additional Subscription Commitments of Approximately SEK 7 million in the ongoing Rights Issue
SOURCE: AlzeCure Pharma
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Red Rock Resorts (RRR) Reports Q2: Everything You Need To Know Ahead Of Earnings
Casino resort and entertainment company Red Rock Resorts (NASDAQ:RRR) will be announcing earnings results this Tuesday after the bell. Here's what investors should know. Red Rock Resorts beat analysts' revenue expectations by 0.6% last quarter, reporting revenues of $497.9 million, up 1.8% year on year. It was a satisfactory quarter for the company, with an impressive beat of analysts' EPS estimates but a miss of analysts' Casino revenue estimates. Is Red Rock Resorts a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Red Rock Resorts's revenue to be flat year on year at $485.4 million, slowing from the 16.9% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.41 per share. Heading into earnings, analysts covering the company have grown increasingly bearish with revenue estimates seeing 4 downward revisions over the last 30 days (we track 10 analysts). Red Rock Resorts has missed Wall Street's revenue estimates three times over the last two years. Looking at Red Rock Resorts's peers in the consumer discretionary segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Monarch delivered year-on-year revenue growth of 6.8%, beating analysts' expectations by 5.4%, and Boyd Gaming reported revenues up 6.9%, topping estimates by 5.4%. Monarch traded up 20.4% following the results while Boyd Gaming was also up 4.1%. Read our full analysis of Monarch's results here and Boyd Gaming's results here. There has been positive sentiment among investors in the consumer discretionary segment, with share prices up 10.3% on average over the last month. Red Rock Resorts is up 8.9% during the same time and is heading into earnings with an average analyst price target of $57.77 (compared to the current share price of $56.64). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 minutes ago
- Yahoo
Landstar Earnings: What To Look For From LSTR
Freight delivery company Landstar (NASDAQ:LSTR) will be announcing earnings results this Tuesday afternoon. Here's what investors should know. Landstar beat analysts' revenue expectations by 1.4% last quarter, reporting revenues of $1.16 billion, down 1.6% year on year. It was a mixed quarter for the company, with a decent beat of analysts' Van Equipment revenue estimates but a miss of analysts' EBITDA estimates. Is Landstar a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Landstar's revenue to decline 1.6% year on year to $1.21 billion, improving from the 10.7% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.17 per share. Heading into earnings, analysts covering the company have grown increasingly bullish with revenue estimates seeing 4 upward revisions over the last 30 days (we track 10 analysts). Landstar has missed Wall Street's revenue estimates five times over the last two years. Looking at Landstar's peers in the ground transportation segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Saia posted flat year-on-year revenue, beating analysts' expectations by 1.2%, and Knight-Swift Transportation reported flat revenue, in line with consensus estimates. Knight-Swift Transportation's stock price was unchanged following the results. Read our full analysis of Saia's results here and Knight-Swift Transportation's results here. There has been positive sentiment among investors in the ground transportation segment, with share prices up 6.8% on average over the last month. Landstar's stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $141.29 (compared to the current share price of $139.87). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Yahoo
an hour ago
- Yahoo
US, China to launch new talks on tariff truce extension, easing path for Trump-Xi meeting
By David Lawder STOCKHOLM (Reuters) -Top U.S. and Chinese economic officials will resume talks in Stockholm on Monday to try to tackle longstanding economic disputes at the centre of a trade war between the world's top two economies, aiming to extend a truce by three months and keeping sharply higher tariffs at bay. China is facing an August 12 deadline to reach a durable tariff agreement with President Donald Trump's administration, after Beijing and Washington reached preliminary deals in May and June to end weeks of escalating tit-for-tat tariffs and a cut-off of rare earth minerals. Without an agreement, global supply chains could face renewed turmoil from U.S. duties snapping back to triple-digit levels that would amount to a bilateral trade embargo. The Stockholm talks come hot on the heels of Trump's biggest trade deal yet with the European Union on Sunday for a 15% tariff on most EU goods exports to the U.S., including autos. The bloc will also buy $750 billion worth of American energy and make $600 billion worth of U.S. investments in coming years. No similar breakthrough is expected in the U.S.-China talks but trade analysts said that another 90-day extension of a tariff and export control truce struck in mid-May was likely. An extension of that length would prevent further escalation and facilitate planning for a potential meeting between Trump and Chinese President Xi Jinping in late October or early November. A U.S. Treasury spokesperson declined comment on a South China Morning Post report quoting unnamed sources as saying the two sides would refrain from introducing new tariffs or other steps that could escalate the trade war for another 90 days. Trump's administration is poised to impose new sectoral tariffs that will impact China within weeks, including on semiconductors, pharmaceuticals, ship-to-shore cranes and other products. "We're very close to a deal with China. We really sort of made a deal with China, but we'll see how that goes," Trump told reporters on Sunday before European Commission President Ursula von der Leyen struck their tariff deal. DEEPER ISSUES Previous U.S.-China trade talks in Geneva and London in May and June focused on bringing U.S. and Chinese retaliatory tariffs down from triple-digit levels and restoring the flow of rare earth minerals halted by China and Nvidia's H20 AI chips and other goods halted by the United States. So far, the talks have not delved into broader economic issues. They include U.S. complaints that China's state-led, export-driven model is flooding world markets with cheap goods, and Beijing's complaints that U.S. national security export controls on tech goods seek to stunt Chinese growth. "Geneva and London were really just about trying to get the relationship back on track so that they could, at some point, actually negotiate about the issues which animate the disagreement between the countries in the first place," said Scott Kennedy, a China economics expert at the Center for Strategic and International Studies in Washington. "I'd be surprised if there is an early harvest on some of these things but an extension of the ceasefire for another 90 days seems to be the most likely outcome," Kennedy said. U.S. Treasury Secretary Scott Bessent has already flagged a deadline extension and has said he wants China to rebalance its economy away from exports to more domestic consumption -- a decades-long goal for U.S. policymakers. Analysts say the U.S.-China negotiations are far more complex than those with other Asian countries and will require more time. China's grip on the global market for rare earth minerals and magnets, used in everything from military hardware to car windshield wiper motors, has proved to be an effective leverage point on U.S. industries. TRUMP-XI MEETING? In the background of the talks is speculation about a possible meeting between Trump and Xi in late October. Trump has said he will decide soon on a landmark trip to China, and a new flare-up of tariffs and export controls would likely derail planning. Sun Chenghao, a fellow at Tsinghua University's Center for International Security and Strategy in Beijing, said that a Trump-Xi summit would be an opportunity for the U.S. to lower the 20% tariffs on Chinese goods related to fentanyl. In exchange, he said the Chinese side could make good on its 2020 pledge to increase purchases of U.S. farm products and other goods. "The future prospect of the heads of state summit is very beneficial to the negotiations because everyone wants to reach an agreement or pave the way in advance," Sun said. Still, China will likely request a reduction of multi-layered U.S. tariffs totaling 55% on most goods and further easing of U.S. high-tech export controls, analysts said. Beijing has argued that such purchases would help reduce the U.S. trade deficit with China, which reached $295.5 billion in 2024.
